 Greenwich LifeSciences Inc NASDAQ: GLSI presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. 